Skip to main content
SpringerLink
Log in

Calsequestrin Mutations and Catecholaminergic Polymorphic Ventricular Tachycardia

  • Riley Symposium
  • Published:
Pediatric Cardiology Aims and scope Submit manuscript

Abstract

Cardiac calsequestrin (Casq2) is the major Ca2+ binding protein in the sarcoplasmic reticulum, which is the principle Ca2+ storage organelle of cardiac muscle. During the last decade, experimental studies have provided new concepts on the role of Casq2 in the regulation of cardiac muscle Ca2+ handling. Furthermore, mutations in the gene encoding for cardiac calsequestrin, CASQ2, cause a rare but severe form of catecholaminergic polymorphic ventricular tachycardia (CPVT). Here, we review the physiology of Casq2 in cardiac Ca2+ handling and discuss pathophysiological mechanisms that lead to CPVT caused by CASQ2 mutations. We also describe the clinical aspects of CPVT and provide an update of its contemporary clinical management.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Ackerman MJ, Priori SG, Willems S, Berul C, Brugada R, Calkins H et al (2011) HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies. This document was developed as a partnership between the heart rhythm society (HRS) and the European heart rhythm association (EHRA). Heart Rhythm 8:1308–1339

    Article  PubMed  Google Scholar 

  2. Altschafl BA, Arvanitis DA, Fuentes O, Yuan Q, Kranias EG, Valdivia HH (2011) Dual role of junctin in the regulation of ryanodine receptors and calcium release in cardiac ventricular myocytes. J Physiol 589:6063–6080

    PubMed  CAS  Google Scholar 

  3. Atallah J, Fynn-Thompson F, Cecchin F, DiBardino DJ, Walsh EP, Berul CI (2008) Video-assisted thoracoscopic cardiac denervation: a potential novel therapeutic option for children with intractable ventricular arrhythmias. Ann Thorac Surg 86:1620–1625

    Article  PubMed  Google Scholar 

  4. Baher AA, Uy M, Xie F, Garfinkel A, Qu Z, Weiss JN (2011) Bidirectional ventricular tachycardia: Ping pong in the His-Purkinje system. Heart Rhythm 8(4):599–605

    Article  PubMed  Google Scholar 

  5. Bal NC, Sharon A, Gupta SC, Jena N, Shaikh S, Gyorke S et al (2010) The catecholaminergic polymorphic ventricular tachycardia mutation R33Q disrupts the N-terminal structural motif that regulates reversible calsequestrin polymerization. J Biol Chem 285:17188–17196

    Article  PubMed  CAS  Google Scholar 

  6. Bauce B, Rampazzo A, Basso C, Bagattin A, Daliento L, Tiso N et al (2002) Screening for ryanodine receptor type 2 mutations in families with effort-induced polymorphic ventricular arrhythmias and sudden death: early diagnosis of asymptomatic carriers. J Am Coll Cardiol 40:341–349

    Article  PubMed  CAS  Google Scholar 

  7. Bers DM (2002) Cardiac excitation-contraction coupling. Nature 415:198–205

    Article  PubMed  CAS  Google Scholar 

  8. Berte B, Eyskens B, Meyfroidt G, Willems R (2008) Bidirectional ventricular tachycardia in fulminant myocarditis. Europace 10:767–768

    Article  PubMed  Google Scholar 

  9. Cala SE, Jones LR (1983) Rapid purification of calsequestrin from cardiac and skeletal muscle sarcoplasmic reticulum vesicles by Ca2+-dependent elution from phenyl-sepharose. J Biol Chem 258:11932–11936

    PubMed  CAS  Google Scholar 

  10. Campbell KP, MacLennan DH, Jorgensen AO, Mintzer MC (1983) Purification and characterization of calsequestrin from canine cardiac sarcoplasmic reticulum and identification of the 53,000 dalton glycoprotein. J Biol Chem 258:1197–1204

    PubMed  CAS  Google Scholar 

  11. Cerrone M, Noujaim SF, Tolkacheva EG, Talkachou A, O’Connell R, Berenfeld O et al (2007) Arrhythmogenic mechanisms in a mouse model of catecholaminergic polymorphic ventricular tachycardia. Circ Res 101:1039–1048

    Article  PubMed  CAS  Google Scholar 

  12. Chopra N, Kannankeril PJ, Yang T, Hlaing T, Holinstat I, Ettensohn K et al (2007) Modest reductions of cardiac calsequestrin increase sarcoplasmic reticulum Ca2+ leak independent of luminal Ca2+ and trigger ventricular arrhythmias in mice. Circ Res 101:617–626

    Article  PubMed  CAS  Google Scholar 

  13. Chopra N, Yang T, Asghari P, Moore ED, Huke S, Akin B et al (2009) Ablation of triadin causes loss of cardiac Ca2+ release units, impaired excitation-contraction coupling, and cardiac arrhythmias. Proc Natl Acad Sci USA 106:7636–7641

    Article  PubMed  CAS  Google Scholar 

  14. de la Fuente S, Van Langen IM, Postma AV, Bikker H, Meijer A (2008) A case of catecholaminergic polymorphic ventricular tachycardia caused by two calsequestrin 2 mutations. Pacing Clin Electrophysiol 31:916–919

    Article  PubMed  Google Scholar 

  15. di Barletta MR, Viatchenko-Karpinski S, Nori A, Memmi M, Terentyev D, Turcato F et al (2006) Clinical phenotype and functional characterization of CASQ2 mutations associated with catecholaminergic polymorphic ventricular tachycardia. Circulation 114:1012–1019

    Article  PubMed  Google Scholar 

  16. Endo M, Tanaka M, Ogawa Y (1970) Calcium induced release of calcium from the sarcoplasmic reticulum of skinned skeletal muscle fibres. Nature 228:34–36

    Article  PubMed  CAS  Google Scholar 

  17. Fabiato A, Fabiato F (1975) Contractions induced by a calcium-triggered release of calcium from the sarcoplasmic reticulum of single skinned cardiac cells. J Physiol 249:469–495

    PubMed  CAS  Google Scholar 

  18. Fabiato A (1983) Calcium-induced release of calcium from the cardiac sarcoplasmic reticulum. Am J Physiol 245:C1–C14

    PubMed  CAS  Google Scholar 

  19. Flucher BE, Franzini-Armstrong C (1996) Formation of junctions involved in excitation-contraction coupling in skeletal and cardiac muscle. Proc Natl Acad Sci USA 93:8101–8106

    Article  PubMed  CAS  Google Scholar 

  20. Grimard C, De Labriolle A, Charbonnier B, Babuty D (2005) Bidirectional ventricular tachycardia resulting from digoxin toxicity. J Cardiovasc Electrophysiol 16:807–808

    Article  PubMed  Google Scholar 

  21. Gyorke I, Hester N, Jones LR, Gyorke S (2004) The role of calsequestrin, triadin, and junctin in conferring cardiac ryanodine receptor responsiveness to luminal calcium. Biophys J 86:2121–2128

    Article  PubMed  Google Scholar 

  22. Gyorke S, Terentyev D (2008) Modulation of ryanodine receptor by luminal calcium and accessory proteins in health and cardiac disease. Cardiovasc Res 77:245–255

    Article  PubMed  CAS  Google Scholar 

  23. Han P, Cai W, Wang Y, Lam CK, Arvanitis DA, Singh VP et al (2011) Catecholaminergic-induced arrhythmias in failing cardiomyocytes associated with human HRCS96A variant overexpression. Am J Physiol Heart Circ Physiol 301:H1588–H1595

    Article  PubMed  CAS  Google Scholar 

  24. Hayashi M, Denjoy I, Extramiana F, Maltret A, Buisson NR, Lupoglazoff JM et al (2009) Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricular tachycardia. Circulation 119:2426–2434

    Article  PubMed  CAS  Google Scholar 

  25. Hilliard FA, Steele DS, Laver D, Yang Z, Le Marchand SJ, Chopra N et al (2010) Flecainide inhibits arrhythmogenic Ca2+ waves by open state block of ryanodine receptor Ca2+ release channels and reduction of Ca2+ spark mass. J Mol Cell Cardiol 48:293–301

    Article  PubMed  CAS  Google Scholar 

  26. Hwang HS, Hasdemir C, Laver D, Mehra D, Turhan K, Faggioni M et al (2011) Inhibition of cardiac Ca2+ release channels (RyR2) determines efficacy of class I antiarrhythmic drugs in catecholaminergic polymorphic ventricular tachycardia. Circ Arrhythm Electrophysiol 4:128–135

    Article  PubMed  CAS  Google Scholar 

  27. Ikemoto N, Ronjat M, Meszaros LG, Koshita M (1989) Postulated role of calsequestrin in the regulation of calcium release from sarcoplasmic reticulum. Biochemistry 28:6764–6771

    Article  PubMed  CAS  Google Scholar 

  28. Jones LR, Cala SE (1981) Biochemical evidence for functional heterogeneity of cardiac sarcoplasmic reticulum vesicles. J Biol Chem 256:11809–11818

    PubMed  CAS  Google Scholar 

  29. Jones LR, Zhang L, Sanborn K, Jorgensen AO, Kelley J (1995) Purification, primary structure, and immunological characterization of the 26 kDa calsequestrin binding protein (junctin) from cardiac junctional sarcoplasmic reticulum. J Biol Chem 270:30787–30796

    Article  PubMed  CAS  Google Scholar 

  30. Jones LR, Suzuki YJ, Wang W, Kobayashi YM, Ramesh V, Franzini-Armstrong C et al (1998) Regulation of Ca2+ signaling in transgenic mouse cardiac myocytes overexpressing calsequestrin. J Clin Invest 101:1385–1393

    Article  PubMed  CAS  Google Scholar 

  31. Kang G, Giovannone SF, Liu N, Liu FY, Zhang J, Priori SG et al (2010) Purkinje cells from RyR2 mutant mice are highly arrhythmogenic but responsive to targeted therapy. Circ Res 107:512–519

    Article  PubMed  CAS  Google Scholar 

  32. Kashimura TBS, Trafford AW, Napolitano C, Priori SG, Eisner DA, Venetucci LA (2010) In the RyR2(R4496C) mouse model of CPVT, β-adrenergic stimulation induces Ca waves by increasing SR Ca content and not by decreasing the threshold for Ca waves. Circ Res 107:1483–1489

    Article  PubMed  CAS  Google Scholar 

  33. Kirchhefer U, Wehrmeister D, Postma AV, Pohlentz G, Mormann M, Kucerova D et al (2010) The human CASQ2 mutation K206N is associated with hyperglycosylation and altered cellular calcium handling. J Mol Cell Cardiol 49:95–105

    Article  PubMed  CAS  Google Scholar 

  34. Knollmann BC, Chopra N, Hlaing T, Akin B, Yang T, Ettensohn K et al (2006) Casq2 deletion causes sarcoplasmic reticulum volume increase, premature Ca2+ release, and catecholaminergic polymorphic ventricular tachycardia. J Clin Invest 116:2510–2520

    PubMed  CAS  Google Scholar 

  35. Knollmann BC, Schober T, Petersen AO, Sirenko SG, Franz MR (2007) Action potential characterization in intact mouse heart: steady-state cycle length dependence and electrical restitution. Am J Physiol Heart Circ Physiol 292:H614–H621

    Article  PubMed  CAS  Google Scholar 

  36. Knollmann BC, Roden DM (2008) A genetic framework for improving arrhythmia therapy. Nature 451:929–936

    Article  PubMed  CAS  Google Scholar 

  37. Knollmann BC (2009) New roles of calsequestrin and triadin in cardiac muscle. J Physiol 587:3081–3087

    Article  PubMed  CAS  Google Scholar 

  38. Knollmann BC (2011) Carvedilol tweaks calcium release to ease arrhythmias. Nat Med 17:923–924

    Article  PubMed  CAS  Google Scholar 

  39. Kobayashi YM, Jones LR (1999) Identification of triadin 1 as the predominant triadin isoform expressed in mammalian myocardium. J Biol Chem 274:28660–28668

    Article  PubMed  CAS  Google Scholar 

  40. Kornyeyev D, Petrosky AD, Zepeda B, Ferreiro M, Knollmann B, Escobar AL (2011) Calsequestrin 2 deletion shortens the refractoriness of Ca(2+) release and reduces rate-dependent Ca(2+)-alternans in intact mouse hearts. J Mol Cell Cardiol 52:21–31

    Article  PubMed  Google Scholar 

  41. Lahat H, Eldar M, Levy-Nissenbaum E, Bahan T, Friedman E, Khoury A et al (2001) Autosomal recessive catecholamine- or exercise-induced polymorphic ventricular tachycardia: clinical features and assignment of the disease gene to chromosome 1p13-21. Circulation 103:2822–2827

    Article  PubMed  CAS  Google Scholar 

  42. Lahat H, Pras E, Olender T, Avidan N, Ben-Asher E, Man O et al (2001) A missense mutation in a highly conserved region of CASQ2 is associated with autosomal recessive catecholamine-induced polymorphic ventricular tachycardia in Bedouin families from Israel. Am J Hum Genet 69:1378–1384

    Article  PubMed  CAS  Google Scholar 

  43. Leenhardt A, Lucet V, Denjoy I, Grau F, Ngoc DD, Coumel P (1995) Catecholaminergic polymorphic ventricular tachycardia in children. A 7-year follow-up of 21 patients. Circulation 91:1512–1519

    Article  PubMed  CAS  Google Scholar 

  44. Lehnart SE, Wehrens XH, Marks AR (2004) Calstabin deficiency, ryanodine receptors, and sudden cardiac death. Biochem Biophys Res Commun 322:1267–1279

    Article  PubMed  CAS  Google Scholar 

  45. Lehnart SE, Mongillo M, Bellinger A, Lindegger N, Chen BX, Hsueh W et al (2008) Leaky Ca2+ release channel/ryanodine receptor 2 causes seizures and sudden cardiac death in mice. J Clin Invest 118:2230–2245

    PubMed  CAS  Google Scholar 

  46. Li P, Rudy Y (2011) A model of canine Purkinje cell electrophysiology and Ca(2+) cycling: rate dependence, triggered activity, and comparison to ventricular myocytes. Circ Res 109:71–79

    Article  PubMed  CAS  Google Scholar 

  47. Liu N, Ruan Y, Priori SG (2008) Catecholaminergic polymorphic ventricular tachycardia. Prog Cardiovasc Dis 51:23–30

    Article  PubMed  Google Scholar 

  48. Liu N, Ruan Y, Denegri M, Bachetti T, Li Y, Colombi B et al (2010) Calmodulin kinase II inhibition prevents arrhythmias in RyR2(R4496C+/−) mice with catecholaminergic polymorphic ventricular tachycardia. J Mol Cell Cardiol 50:214–222

    Article  PubMed  Google Scholar 

  49. Liu N, Denegri M, Ruan Y, Avelino-Cruz JE, Perissi A, Negri S et al (2011) Short communication: flecainide exerts an antiarrhythmic effect in a mouse model of catecholaminergic polymorphic ventricular tachycardia by increasing the threshold for triggered activity. Circ Res 109:291–295

    Article  PubMed  CAS  Google Scholar 

  50. Liu QQ, Oberti C, Zhang XQ, Ke T, Zhang T, Scheinman M et al (2008) A novel mutation of F189L in CASQ2 in families with catecholaminergic polymorphic ventricular tachycardia. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 25:334–337

    PubMed  CAS  Google Scholar 

  51. Maruyama M, Lin SF, Chen PS (2010) Alternans of diastolic intracellular calcium elevation as the mechanism of bidirectional ventricular tachycardia in a rabbit model of Andersen–Tawil syndrome. Heart Rhythm [Epub Dec 15]

  52. Mohamed U, Gollob MH, Gow RM, Krahn AD (2006) Sudden cardiac death despite an implantable cardioverter-defibrillator in a young female with catecholaminergic ventricular tachycardia. Heart Rhythm 3:1486–1489

    Article  PubMed  Google Scholar 

  53. Mohamed U, Napolitano C, Priori SG (2007) Molecular and electrophysiological bases of catecholaminergic polymorphic ventricular tachycardia. J Cardiovasc Electrophysiol 18:791–797

    Article  PubMed  Google Scholar 

  54. Morris SN, Zipes DP (1973) His bundle electrocardiography during bidirectional tachycardia. Circulation 48:32–36

    Article  PubMed  CAS  Google Scholar 

  55. Murphy RM, Mollica JP, Beard NA, Knollmann BC, Lamb GD (2011) Quantification of calsequestrin 2 (CSQ2) in sheep cardiac muscle and Ca2+-binding protein changes in CSQ2 knockout mice. Am J Physiol Heart Circ Physiol 300:H595–H604

    Article  PubMed  CAS  Google Scholar 

  56. Murphy RM, Mollica JP, Beard NA, Knollmann BC, Lamb GD (2011) Quantification of calsequestrin 2 (CSQ2) in sheep cardiac muscle and Ca2+-binding protein changes in CSQ2 knockout mice. Am J Physiol Heart Circ Physiol 300:H595–H604

    Article  PubMed  CAS  Google Scholar 

  57. Napolitano C, Priori SG (2007) Diagnosis and treatment of catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm 4:675–678

    Article  PubMed  Google Scholar 

  58. Park H, Wu S, Dunker AK, Kang C (2003) Polymerization of calsequestrin. Implications for Ca2+ regulation. J Biol Chem 278:16176–16182

    Article  PubMed  CAS  Google Scholar 

  59. Pizzale S, Gollob MH, Gow R, Birnie DH (2008) Sudden death in a young man with catecholaminergic polymorphic ventricular tachycardia and paroxysmal atrial fibrillation. J Cardiovasc Electrophysiol 19:1319–1321

    Article  PubMed  Google Scholar 

  60. Postma AV, Denjoy I, Hoorntje TM, Lupoglazoff JM, Da Costa A, Sebillon P et al (2002) Absence of calsequestrin 2 causes severe forms of catecholaminergic polymorphic ventricular tachycardia. Circ Res 91:e21–e26

    Article  PubMed  CAS  Google Scholar 

  61. Postma AV, Denjoy I, Kamblock J, Alders M, Lupoglazoff JM, Vaksmann G et al (2005) Catecholaminergic polymorphic ventricular tachycardia: RYR2 mutations, bradycardia, and follow up of the patients. J Med Genet 42:863–870

    Article  PubMed  CAS  Google Scholar 

  62. Priori SG, Napolitano C, Tiso N, Memmi M, Vignati G, Bloise R et al (2001) Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia. Circulation 103:196–200

    Article  PubMed  CAS  Google Scholar 

  63. Priori SG, Napolitano C, Memmi M, Colombi B, Drago F, Gasparini M et al (2002) Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. Circulation 106:69–74

    Article  PubMed  CAS  Google Scholar 

  64. Priori SG, Chen SR (2011) Inherited dysfunction of sarcoplasmic reticulum Ca2+ handling and arrhythmogenesis. Circ Res 108:871–883

    Article  PubMed  CAS  Google Scholar 

  65. Rizzi N, Liu N, Napolitano C, Nori A, Turcato F, Colombi B et al (2008) Unexpected structural and functional consequences of the R33Q homozygous mutation in cardiac calsequestrin: a complex arrhythmogenic cascade in a knock in mouse model. Circ Res 103:298–306

    Article  PubMed  CAS  Google Scholar 

  66. Rosso R, Kalman JM, Rogowski O, Diamant S, Birger A, Biner S et al (2007) Calcium channel blockers and beta-blockers versus beta-blockers alone for preventing exercise-induced arrhythmias in catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm 4:1149–1154

    Article  PubMed  Google Scholar 

  67. Sedej S, Heinzel FR, Walther S, Dybkova N, Wakula P, Groborz J et al (2010) Na+-dependent SR Ca2+ overload induces arrhythmogenic events in mouse cardiomyocytes with a human CPVT mutation. Cardiovasc Res 87:50–59

    Article  PubMed  CAS  Google Scholar 

  68. Song L, Alcalai R, Arad M, Wolf CM, Toka O, Conner DA et al (2007) Calsequestrin 2 (CASQ2) mutations increase expression of calreticulin and ryanodine receptors, causing catecholaminergic polymorphic ventricular tachycardia. J Clin Invest 117:1814–1823

    Article  PubMed  CAS  Google Scholar 

  69. Sonmez O, Gul EE, Duman C, Duzenli MA, Tokac M, Cooper J (2009) Type II bidirectional ventricular tachycardia in a patient with myocardial infarction. J Electrocardiol 42:631–632

    Article  PubMed  Google Scholar 

  70. Stevens SC, Terentyev D, Kalyanasundaram A, Periasamy M, Gyorke S (2009) Intra-sarcoplasmic reticulum Ca2+ oscillations are driven by dynamic regulation of ryanodine receptor function by luminal Ca2+ in cardiomyocytes. J Physiol 587:4863–4872

    Article  PubMed  CAS  Google Scholar 

  71. Sumitomo N, Harada K, Nagashima M, Yasuda T, Nakamura Y, Aragaki Y et al (2003) Catecholaminergic polymorphic ventricular tachycardia: electrocardiographic characteristics and optimal therapeutic strategies to prevent sudden death. Heart 89:66–70

    Article  PubMed  CAS  Google Scholar 

  72. Swan H, Piippo K, Viitasalo M, Heikkila P, Paavonen T, Kainulainen K et al (1999) Arrhythmic disorder mapped to chromosome 1q42-q43 causes malignant polymorphic ventricular tachycardia in structurally normal hearts. J Am Coll Cardiol 34:2035–2042

    Article  PubMed  CAS  Google Scholar 

  73. Swan H, Laitinen P, Kontula K, Toivonen L (2005) Calcium channel antagonism reduces exercise-induced ventricular arrhythmias in catecholaminergic polymorphic ventricular tachycardia patients with RyR2 mutations. J Cardiovasc Electrophysiol 16:162–166

    Article  PubMed  Google Scholar 

  74. Terentyev D, Nori A, Santoro M, Viatchenko-Karpinski S, Kubalova Z, Gyorke I et al (2006) Abnormal interactions of calsequestrin with the ryanodine receptor calcium release channel complex linked to exercise-induced sudden cardiac death. Circ Res 98:1151–1158

    Article  PubMed  CAS  Google Scholar 

  75. van der Werf C, Kannankeril PJ, Sacher F, Krahn AD, Viskin S, Leenhardt A et al (2011) Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia. J Am Coll Cardiol 57:2244–2254

    Article  PubMed  Google Scholar 

  76. Wang S, Trumble WR, Liao H, Wesson CR, Dunker AK, Kang CH (1998) Crystal structure of calsequestrin from rabbit skeletal muscle sarcoplasmic reticulum. Nat Struct Biol 5:476–483

    Article  PubMed  CAS  Google Scholar 

  77. Watanabe H, Chopra N, Laver D, Hwang HS, Davies SS, Roach DE et al (2009) Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. Nat Med 15:380–383

    Article  PubMed  CAS  Google Scholar 

  78. Watanabe H, Knollmann BC (2011) Mechanism underlying catecholaminergic polymorphic ventricular tachycardia and approaches to therapy. J Electrocardiol 44:650–655

    Article  PubMed  Google Scholar 

  79. Wilde AA, Bhuiyan ZA, Crotti L, Facchini M, De Ferrari GM, Paul T et al (2008) Left cardiac sympathetic denervation for catecholaminergic polymorphic ventricular tachycardia. N Engl J Med 358:2024–2029

    Article  PubMed  CAS  Google Scholar 

  80. Wong CH, Koo SH, She GQ, Chui P, Lee EJ (2009) Genetic variability of RyR2 and CASQ2 genes in an Asian population. Forensic Sci Int 192:53–55

    Article  PubMed  CAS  Google Scholar 

  81. Xie Y, Sato D, Garfinkel A, Qu Z, Weiss JN (2010) So little source, so much sink: requirements for after depolarizations to propagate in tissue. Biophys J 99:1408–1415

    Article  PubMed  CAS  Google Scholar 

  82. Yuan Q, Fan GC, Dong M, Altschafl B, Diwan A, Ren X et al (2007) Sarcoplasmic reticulum calcium overloading in junctin deficiency enhances cardiac contractility but increases ventricular automaticity. Circulation 115:300–309

    Article  PubMed  CAS  Google Scholar 

  83. Zhang L, Kelley J, Schmeisser G, Kobayashi YM, Jones LR (1997) Complex formation between junctin, triadin, calsequestrin, and the ryanodine receptor. Proteins of the cardiac junctional sarcoplasmic reticulum membrane. J Biol Chem 272:23389–23397

    Article  PubMed  CAS  Google Scholar 

  84. Zhou Q, Xiao J, Jiang D, Wang R, Vembaiyan K, Wang A et al (2011) Carvedilol and its new analogs suppress arrhythmogenic store overload-induced Ca(2+) release. Nat Med 17(8):1003–1009

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This work was supported in part by United States National Institutes of Health Grants No. HL88635 and HL71670 (to B. C. K), by the American Heart Association Established Investigator Award 0840071 N (to B. C. K.), and by a Heart Rhythm Society Fellowship Award (to M. F.). We thank Frank Fish and Prince Kannankeril for providing the ECG examples as well as their editorial suggestions.

Disclosures

None declared.

Author information

Authors and Affiliations

  1. Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, 37232-0575, USA

    Michela Faggioni, Dmytro O. Kryshtal & Björn C. Knollmann

  2. Division of Clinical Pharmacology, Vanderbilt University School of Medicine, Nashville, TN, 37232-0575, USA

    Michela Faggioni, Dmytro O. Kryshtal & Björn C. Knollmann

Authors
  1. Michela Faggioni
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dmytro O. Kryshtal
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Björn C. Knollmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Björn C. Knollmann.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Faggioni, M., Kryshtal, D.O. & Knollmann, B.C. Calsequestrin Mutations and Catecholaminergic Polymorphic Ventricular Tachycardia. Pediatr Cardiol 33, 959–967 (2012). https://doi.org/10.1007/s00246-012-0256-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00246-012-0256-1

Keywords

Search

Navigation